LIXTE BIOTECHNOLOGY HOLDINGS, INC.

LIXTE Biotechnology Holdings, Inc. announced a definitive agreement to acquire 100% of NOMAD Transportable Power Systems, Inc., a market leader in deployable, utility-grade battery energy storage systems. Upon closing, LIXTE will be renamed NOMAD Power Solutions, marking a significant strategic shift from biotechnology to power solutions. NOMAD reported approximately 175% revenue growth in 2025 and projects 135% growth in 2026, addressing a multi-hundred-billion-dollar power capacity opportunity.

LIXTE Biotechnology Holdings, Inc. announced it has entered into definitive agreements for a registered direct offering with accredited investors, expecting to raise approximately $16.57 million. The offering, priced at market under Nasdaq rules, includes the sale of 2,625,362 shares of common stock and pre-funded warrants at $6.31 per share and $0.0001 per warrant, respectively. This financing is intended to materially strengthen the company's balance sheet, provide flexibility for strategic priorities, and support general corporate purposes and working capital. The company also highlighted the recent appointment of Stuart D. Porter to its Board of Directors.

LIXTE Biotechnology Holdings, Inc. announced a strategic transformation into an AI energy infrastructure equipment & services platform to meet the rapidly growing power demands of AI and hyperscale data centers. Concurrently, Stuart D. Porter, Founder and CEO of Denham Capital, was appointed to the Board of Directors, bringing over three decades of energy investment experience. The company also plans to seek a strategic acquisition partner for its existing clinical stage pharmaceutical and med-tech operations.

LIXTE Biotechnology Holdings, Inc. announced a strategic transformation into an AI energy infrastructure equipment and services platform to address the growing power demands of AI and hyperscale data centers. Concurrently, Stuart D. Porter, Founder of Denham Capital Management LP, has joined the Company's Board of Directors. LIXTE also stated it will seek a strategic acquisition partner for its existing clinical-stage pharmaceutical and med-tech operations focused on cancer treatments.

LIXTE Biotechnology Holdings announced the filing of its Quarterly Report on Form 10-Q for the first quarter ended March 31, 2026. The company highlighted significant progress in advancing its lead compound, LB-100, including the expansion of its ovarian cancer trial following favorable safety results with GSK's dostarlimab. Additionally, LIXTE reported continued growth and strategic development of its Liora Technologies Europe subsidiary, which focuses on proton therapy solutions. The company also presented favorable preliminary results for the LB-100 and dostarlimab combination at a recent conference.

Lixte Biotechnology Holdings, Inc. has entered into a Restricted Share Unit Award Agreement, granting RSUs under its 2020 Stock Incentive Plan. These units are awarded in exchange for services, with immediate vesting upon the grant date, contingent on continuous service. Each vested RSU will be settled by issuing one common share within 60 days, and grantees will also receive dividend equivalent units.

LIXTE Biotechnology announced preliminary clinical trial results for its LB-100 compound combined with Dostarlimab for ovarian clear cell carcinoma. The trial showed an acceptable safety profile and a 40% Disease Control Rate (DCR) among 20 evaluated patients. With a median follow-up of 12 months, the overall survival probability was 0.69 at 12 months, offering new hope for patients with limited therapeutic options. An additional cohort of 21 patients is now enrolling to test higher LB-100 exposure.